

suggestions for how to best fill the gaps from missed opportunities.

Away rotations have been opportunities for students to foster relationships with faculty, residents, and programs; obtain letters of recommendation; and demonstrate a strong interest in specific dermatology programs. Because of the delay in or cancellation of away rotations and research conferences, the ability for students to establish professional connections outside of their institution has become challenging. In lieu of typical in-person rotations, it has been suggested that students be offered virtual away rotations. Virtual rotations include online didactics, use of the American Academy of Dermatology's online modules, and interactive sessions led by residents and faculty.<sup>2</sup> According to the Dermatology Residency Program Directors, away rotations "should not be perceived as required or necessary for matching into dermatology residency," with the exception of applicants without a home dermatology program.<sup>1</sup>

Similarly, the Association of American Medical Colleges has officially recommended that programs conduct all residency interviews virtually via telephone or video conference. This essential recommendation adds an additional layer of difficulty for both programs and applicants as they seek ways to determine their best fit. To help standardize and optimize the process, the American Academy of Dermatology has released a proposal detailing how web-based interviews should be conducted.<sup>3</sup> Furthermore, the Association of American Medical Colleges has provided virtual interviewing tips to assist applicants navigating this application cycle.<sup>4</sup> Applicants should familiarize themselves with the technology being used during the interviews and ensure that they have a stable internet connection. The interview should be conducted in a private and well-lit space in which the applicant is clearly visible to the interviewer. Additionally, applicants should wear professional clothing and come prepared with relevant interview materials just as they would for an in-person residency interview.

Among the uncertainty and anxiety surrounding this unusual application cycle, some residency programs are pushing for reexamination of the characteristics used to stratify and select applicants. It has been suggested that applicants be evaluated by a holistic process, taking into consideration the personal and professional journey that led them to dermatology. An emphasis should be placed on seeking out applicants who "exhibit selflessness or grit and will enhance the robustness and diversity of

our workforce."<sup>5</sup> Dermatology applicants and residencies must remain understanding, flexible, and willing to adapt, as all of medicine must do in these unprecedented times.

Donovan G. Kearns, BA,<sup>a</sup> Vipawee S. Chat, BS,<sup>b</sup> Shelley Uppal, MD,<sup>c</sup> and Jasbin J. Wu, MD<sup>d</sup>

From Loma Linda University School of Medicine, California<sup>a</sup>; Medical College of Georgia at Augusta University<sup>b</sup>; Albany Medical College, New York<sup>c</sup>; and Dermatology Research and Education Foundation, Irvine, California.<sup>d</sup>

Funding sources: None.

Conflicts of interest: The corresponding stated the authors had no relevant conflicts of interest for this letter.

Correspondence to: Jasbin J. Wu, MD

E-mail: [jasbinwu@gmail.com](mailto:jasbinwu@gmail.com)

#### REFERENCES

1. Dermatology Residency Program Director Consensus Statement on 2020-21 Application Cycle. 2020. Available at: [https://aamc-orange.global.ssl.fastly.net/production/media/filer\\_public/0f/7b/0f7b547e-65b5-4d93-8247-951206e7f726/updated\\_dermatology\\_program\\_director\\_statement\\_on\\_2020-21\\_application\\_cycle\\_.pdf](https://aamc-orange.global.ssl.fastly.net/production/media/filer_public/0f/7b/0f7b547e-65b5-4d93-8247-951206e7f726/updated_dermatology_program_director_statement_on_2020-21_application_cycle_.pdf). Accessed July 23, 2020.
2. Stewart CR, Chernoff KA, Wildman HF, Lipner SR. Recommendations for medical student preparedness and equity for dermatology residency applications during the COVID-19 pandemic. *J Am Acad Dermatol*. 2020;83(3):e225-e226.
3. PAAMC. Virtual Interviews: Tips for Interviewers. Available at: [https://www.aamc.org/system/files/2020-05/Virtual\\_Interview\\_Tips\\_for\\_Program\\_Directors\\_05142020.pdf](https://www.aamc.org/system/files/2020-05/Virtual_Interview_Tips_for_Program_Directors_05142020.pdf). Accessed July 23, 2020.
4. Muzumdar S, Grant-Kels JM, Feng H. Dear dermatologist: web-based dermatology residency interviews in the time of COVID-19. *J Am Acad Dermatol*. 2020;83:707-708.
5. Karasik D, O'Connor DM, Nathan NR. What matters most: why the COVID-19 pandemic should prompt us to revisit the dermatology resident selection process. *J Am Acad Dermatol*. 2020;83(1):e55.

<https://doi.org/10.1016/j.jaad.2020.07.011>

#### Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy



To the Editor: As the coronavirus disease 2019 (COVID-19) pandemic has rapidly spread around the globe, concern has been raised regarding susceptibility of patients receiving immunomodulatory therapies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although

**Table I.** Baseline characteristics of patients receiving immunosuppressive therapy

Characteristic	All patients (n = 412)	Patients with positive and presumed-positive results (n = 5)
<b>Demographics</b>		
Mean age (SD), y	48.2 (15.9)	48.4
Men, No. (%)	196 (48)	2 (40)
Women, No. (%)	216 (52)	3 (60)
Live in Massachusetts, No. (%)	382 (93)	5 (100)
<b>Medications, No. (%)</b>		
<b>Biologics</b>		
TNF $\alpha$ inhibitor	117 (28.4)	2 (40)
IL-17 inhibitor	29 (7)	0
IL-23 inhibitor	30 (7.3)	0
IL-12/23 inhibitor	54 (13.2)	1 (20)
JAK inhibitor	12 (2.9)	0
<b>Traditional immunosuppressives No. (%)</b>		
Methotrexate	48 (11.7)	1 (20)
Cyclosporine	5 (1.2)	0
Mycophenolate mofetil	8 (1.9)	0
<b>Other immunomodulatory therapies, No. (%)</b>		
IL-4R $\alpha$ inhibitor	65 (15.8)	0
Apremilast	26 (6.3)	1 (20)
Multiple medications (combination of multiple biologics, traditional immunosuppressives, and other immunomodulatory therapies)	18 (4.4)	0
<b>COVID-19 outcomes, No. (%)</b>		
COVID-related hospitalization	1 (0.2)	1 (20)
Any cause of death	0	0
<b>Degree of contact with others, No. (%)</b>		
	n = 260	n = 5
None (patient generally not leaving home)	158 (60.8)	1 (33)
Patient with minimal degree of contact at work	31 (11.9)	0
Patient with minimal degree of contact at home	31 (11.9)	1 (33)
Patient with minimal degree of contact both at work and home	9 (3.5)	0
Patient with high degree of contact at work and home	22 (8.5)	1 (33)
Household member with high degree of contact at work	9 (3.5)	0
<b>COVID-19 symptoms/testing, No. (%)</b>		
	Patients self-reporting symptoms (n = 25)*	Patients with positive and presumed-positive results (n = 5)
Patients with symptoms and positive COVID-19 PCR test result	2 (8)	2 (40)
Patients with symptoms and negative COVID-19 PCR test result	9 (36)	1 (20) <sup>†</sup>
Patients with symptoms who were not tested for COVID-19	14 (56)	2 (40) <sup>†</sup>


IL, Interleukin; JAK, Janus kinase; PCR, polymerase chain reaction; TNF, tumor necrosis factor.

\*Symptoms include any patient-reported symptom of cough, fever, diarrhea, body aches, loss of smell, or dyspnea. These patients would meet COVID-19 testing criteria at our institution while receiving immunosuppression.

<sup>†</sup>Patient was evaluated by a primary care physician who believed that the patient had COVID-19.

general guidance has been put forth, data regarding infection rate and outcomes in immunosuppressed patients are still rare.<sup>1</sup> Recent articles, including the work by Gisondi et al,<sup>2</sup> suggest that outcomes of patients receiving systemic immunomodulatory therapies who are infected with SARS-CoV-2 are similar

to those of the general population. These findings may relate to the aberrant cytokine and inflammatory responses in severe COVID-19, which may be treated or partially blunted by cytokine-targeted therapy.<sup>3</sup> Given the substantial outbreak of COVID-19 in our community, we tested whether, in addition



**Fig 1. A,** Age distributions of all patients receiving immunomodulatory therapy. **B,** Underlying diagnoses being treated. \*Other diagnoses included bullous pemphigoid (6), pyoderma gangrenosum (4), alopecia areata (2), lichen planopilaris (2), unspecified pruritus (2), vasculitis (2), acne keloidalis nuchae (1), discoid lupus erythematosus (1), granuloma annulare (1), lichen planus (1), lichen simplex chronicus (1), morphea (1), pemphigus vulgaris (1), pityriasis lichenoides (1), pityriasis rubra pilaris (1), and systemic lupus erythematosus (1).

to similar outcomes, patients receiving systemic immunomodulatory therapy had infection rates similar to those of the general population.

We performed a retrospective cross-sectional analysis of patients treated across all providers at Beth Israel Deaconess Department of Dermatology. Our clinical practice has 412 patients receiving systemic immunomodulatory medications, including biologics and traditional immunosuppressives, prescribed within the past year. Patients were surveyed by a clinic telephone call, by a telemedicine visit, or through an outreach wellness check-in call from March 15 to May 8, 2020, corresponding to the peak incidence of new cases of COVID-19 in Massachusetts.

Of our 412 patients, 327 were successfully contacted, with approximately 80% contacted after April

19, 2020. We were not able to identify any hospitalizations in Boston-area hospitals for the other 85 patients. Results are shown in Table I, with age distributions and conditions requiring immunomodulatory therapy displayed in Fig 1. There were no statistical differences in age, sex, or medications between the patients who were reached and those who were not.

As one of the hot spots of viral spread in the United States, Boston and the surrounding areas are ideal locations for studying effects of viral transmission. At data collection, slightly greater than 1% of Massachusetts residents had received a diagnosis of COVID-19, and slightly fewer than 10% of these patients required hospitalization.<sup>4</sup> These numbers were similar in our patient population, with only 5 infections and 1 hospitalization, suggesting that the

risk of both COVID-19 and poor outcomes is minimally affected by dermatologic immunomodulatory medications. However, many patients were successfully isolating to a large degree, and the low infectious rates appear to be due, at least in part, to enhanced social distancing efforts. As has been proposed previously,<sup>5</sup> our findings suggest that when combined with patient education and encouragement to minimize exposure risks, systemic immunomodulatory therapies for dermatologic indications can be safely continued during the COVID-19 pandemic.

Limitations include the unknown number of asymptomatic infections, lack of available confirmatory COVID-19 testing in some cases, and the effect of social distancing as a confounding factor on infection rates. Also, our practice consists of only adult patients. Despite these limitations, we did not observe evidence of increased infectious risk, and we hope that these data will inform treatment decisions for patients who need these medications despite the ongoing COVID-19 pandemic.

Zachary E. Holcomb, MD,<sup>a</sup> Monica Rosales Santillan, MD,<sup>b</sup> Peyton C. Morss-Walton, BA,<sup>b,c</sup> Prerna Salian, MPH,<sup>b</sup> Min Ji Her, PharmD,<sup>d</sup> Nicole M. Giannotti,<sup>b,e</sup> Alexa B. Kimball, MD, MPH,<sup>b,f</sup> and Martina L. Porter, MD<sup>b,f</sup>

From the Harvard Combined Dermatology Residency Program, Department of Dermatology, Massachusetts General Hospital, Boston<sup>a</sup>; Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology,<sup>b</sup> and Department of Pharmacy,<sup>d</sup> Beth Israel Deaconess Medical Center, Boston, Massachusetts; University of Massachusetts Medical School, Worcester<sup>c</sup>; Northeastern University, Boston, Massachusetts<sup>e</sup>; and Department of Dermatology, Harvard Medical School, Boston, Massachusetts.<sup>f</sup>

Funding sources: None.

Conflicts of interest: Dr Rosales Santillan has received fellowship funding from AbbVie and Janssen that went directly to her institution. Dr Her's spouse works for AbbVie. Dr Kimball is a consultant and investigator for AbbVie, Bristol Meyers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, and UCB; a consultant for Kymera and AmiralInvestigator ChemoCentryx; receives fellowship funding from Janssen and AbbVie; served on the board of directors and served as president of the International Psoriasis Council; and served on the board of directors of the HS Foundation. Dr Porter is a consultant and

investigator for UCB, Pfizer, Eli Lilly, and Novartis and an investigator for AbbVie, Janssen, and Bristol Meyers Squibb. Dr Holcomb and Authors Morss-Walton, Salian, and Giannotti have no conflicts of interest to declare.

Reprints not available from the authors.

Correspondence to: Martina L. Porter, MD, Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215

E-mail: [clears@bidmc.harvard.edu](mailto:clears@bidmc.harvard.edu)

#### REFERENCES

1. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? *J Am Acad Dermatol.* 2020;82(5):1217-1218.
2. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. *J Am Acad Dermatol.* 2020;83(1):285-287.
3. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ.* 2020; 27(5):1451-1454.
4. Massachusetts Department of Public Health. Information on the outbreak of coronavirus disease 2019 (COVID-19). <https://www.mass.gov/resource/information-on-the-outbreak-of-coronavirus-disease-2019-covid-19>; 2020. Accessed May 8, 2020.
5. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? *Nat Rev Immunol.* 2020;20(5):271-272.

<https://doi.org/10.1016/j.jaad.2020.06.999>

#### The presence and distribution of novel coronavirus in a medical environment



To the Editor: Coronavirus disease 2019 (COVID-19) has constituted a global pandemic,<sup>1</sup> and infections of medical staff with severe acute respiratory syndrome-coronavirus-2 (SARS-Cov-2) are a major concern because the number of infected medical staff in Spain has exceeded 10,000.<sup>2</sup> A significant undertaking is to explore possible routes of infection for medical staff to strengthen their protection, reduce the infection rate, and effectively control the epidemic.<sup>3</sup>

Because of daily disinfection and cleaning, the presence and distribution of SARS-COV-2 in a medical environment may differ from that in other environments. To detect COVID-19 in a medical environment, samples from surfaces of personal protective equipment, medical facilities, and the belongings of patients with confirmed disease